kr483.00
1.60%
Copenhagen, Dec 23, 04:59 pm CET
ISIN
DK0060257814
Symbol
ZEAL

Zealand Pharma Stock price

kr483.00
-58.00 10.72% 1M
+114.40 31.04% 6M
-232.50 32.49% YTD
-237.00 32.92% 1Y
+287.20 146.68% 3Y
+267.00 123.61% 5Y
+335.50 227.46% 10Y
+397.00 461.63% 20Y
Copenhagen, Closing price Tue, Dec 23 2025
+7.60 1.60%
ISIN
DK0060257814
Symbol
ZEAL
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
kr16.2b
Shares outstanding
70.3m
Valuation (TTM | estimate)
P/E
5.2 | 5.2
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
90.7%
Return on Equity
-12.5%
ROCE
46.5%
ROIC
-1,265.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr9.2b | kr9.4b
EBITDA
kr7.3b | kr7.2b
EBIT
kr7.3b | kr7.1b
Net Income
kr6.5b | kr6.5b
Free Cash Flow
kr7.4b
Growth (TTM | estimate)
Revenue
11,809.7% | 14,963.0%
EBITDA
774.2% | 675.4%
EBIT
745.2% | 659.2%
Net Income
721.6% | 703.5%
Free Cash Flow
1,136.3%
Margin (TTM | estimate)
Gross
100.0%
EBITDA
79.7% | 75.8%
EBIT
79.4%
Net
71.5% | 69.0%
Free Cash Flow
80.5%
More
EPS
kr93.1
FCF per Share
kr104.9
Short interest
-
Employees
335
Rev per Employee
kr190.0k
Show more

Is Zealand Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Zealand Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Zealand Pharma forecast:

21x Buy
84%
3x Hold
12%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Zealand Pharma forecast:

Buy
84%
Hold
12%
Sell
4%

Financial data from Zealand Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
9,155 9,155
11,810% 11,810%
100%
- Direct Costs 1.22 1.22
94% 94%
0%
9,154 9,154
16,426% 16,426%
100%
- Selling and Administrative Expenses 558 558
79% 79%
6%
- Research and Development Expense 1,328 1,328
55% 55%
15%
7,293 7,293
774% 774%
80%
- Depreciation and Amortization 26 26
43% 43%
0%
EBIT (Operating Income) EBIT 7,267 7,267
745% 745%
79%
Net Profit 6,543 6,543
722% 722%
71%

In millions DKK.

Don't miss a Thing! We will send you all news about Zealand Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Head office Denmark
CEO Adam Steensberg
Employees 335
Founded 1997
Website www.zealandpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today